Clin2
NCT05458219Possibly a fitRecruiting

Testing an antibody-drug treatment for solid tumors

Locally Advanced Unresectable or Metastatic Solid Tumors

Treatments studied

Part of Cancer clinical trials.

This Phase 1 trial studies a new cancer medicine (IBI343) that targets certain tumor cells to see how safe it is and how well it may work. You may be eligible if you have advanced, hard-to-remove cancers and your tumor has a specific marker called CLDN18.2.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
470 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You agree to join by signing the informed consent form and can attend required study visits.
  • You are 18 or older, and your health/strength score (ECOG) is 0 or 1.
  • Your cancer is advanced and cannot be removed with surgery, and you have at least one tumor area that can be measured (for some parts).
  • Your tumor tissue tests positive for CLDN18.2 (a specific marker on cancer cells), with levels depending on which cancer group you’re in.
  • Your organs and blood counts are strong enough for treatment (bone marrow, liver, kidneys, and blood clotting).
  • You have enough life expectancy for the study (at least 12 weeks) and must avoid pregnancy; use birth control as instructed.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07589205Recruiting· Phase 1
Testing IBI3028 for Advanced Solid Tumors

This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.

Tianjin, Tianjin Municipality
NCT07584954Recruiting· Phase 1
Testing a new cancer immunotherapy in advanced solid tumors

This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.

Fuzhou, Fujian
NCT06963281Recruiting· Phase 1
Study of an experimental drug for late-stage solid tumors

This trial tests an experimental drug called IBI3020 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for these patients.

Pheonix, Arizona
NCT06974812Recruiting· Phase 1/Phase 2
Study of IBI3014 for advanced solid tumors

This trial tests a new drug called IBI3014 for people with advanced solid tumors that cannot be removed by surgery. It aims to see if the drug is safe and effective.

Fuzhou, Fujian
NCT06349408Recruiting· Phase 1
Testing IBI3001 for advanced solid tumors

This trial tests a new drug called IBI3001 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective against different types of cancer.

Wollongong, New South Wales
NCT07327632Recruiting· Early Phase 1
Testing IBI3026 for advanced solid tumors

This study tests a new drug called IBI3026 for people with advanced solid tumors that cannot be surgically removed or have spread. The goal is to see if it is safe and helps control the cancer.

Chengdu, Sichuan

Hear when a new Locally Advanced (Unresectable) or Metastatic Solid Tumors trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.